 CAMBRIDGE, Mass., Dec. 1, 2020 PRNewswire -- Blueprint Medicines Corporation NASDAQ: BPMC, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration FDA has approved GAVRETOTM... 